CPT code 36593 covers administration of a thrombolytic agent, such as tissue plasminogen activator (TPA), to dissolve a clot within an implanted venous access device or catheter. This targeted pharmacologic intervention restores device patency and can prevent device replacement, delays in treatment, and additional procedures. Nationally, the code matters because catheter-directed thrombolysis is commonly used across oncology, long-term infusion therapy, and critical care settings where implanted ports and central venous catheters are maintained.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context for when catheter-directed thrombolytic administration is billed, the typical sites of service where the procedure is performed, and an outline of commonly reported modifiers associated with this service. The publication also summarizes expected documentation elements, incidence of use in device occlusion management, and considerations for billing and claims processing.

This summary is intended for a national audience of clinicians, practice managers, and billing professionals. It highlights what CPT code 36593 represents, the clinical scenarios prompting its use, and the payer landscape relevant to reimbursement and administrative processing. Data not available in the input will be noted where applicable elsewhere in the full publication.